BiotechTube

Vipoglanstat + Placebo

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometriosis

Conditions

Endometriosis

Trial Timeline

Oct 15, 2025 → Jun 1, 2027

NCT ID
NCT07260669

About Vipoglanstat + Placebo

Vipoglanstat + Placebo is a phase 2 stage product being developed by Gesynta Pharma for Endometriosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07260669. Target conditions include Endometriosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07260669Phase 2Recruiting

Competing Products

20 competing products in Endometriosis

See all competitors
ProductCompanyStageHype Score
ASP1707 + Placebo + Leuprorelin acetateAstellas PharmaPhase 2
52
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
77
SHR7280 TabletsJiangsu Hengrui MedicinePhase 1
33
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
33
SHR7280 + Placebo oral tabletJiangsu Hengrui MedicinePhase 1/2
41
SHR7280 Tablet + SHR7280 Placebo TabletJiangsu Hengrui MedicinePhase 1
33
Placebo + ElagolixAbbViePhase 2
52
Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
77
Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
77
ElagolixAbbViePhase 3
77
elagolix + estradiol/norethindrone acetate (E2/NETA)AbbViePhase 3
77
Elagolix + placeboAbbViePhase 2
52
ElagolixAbbViePhase 3
77
Elagolix + Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) + Placebo to Elagolix + Placebo to DMPA-SCAbbViePhase 2
52
elagolixAbbViePhase 3
77
ElagolixAbbViePhase 3
77
Leuprorelin Acetate Depot + Elagolix + Placebo to Elagolix + Placebo to Leuprorelin AcetateAbbViePhase 2
52
Gefapixant + Placebo + NaproxenMerckPhase 2
52
BGS649 + PlaceboNovartisPhase 2
52
Active treatment with a high dose of BGS649 + Active treatment with a low dose of BGS649 + Placebo treatment to blind studyNovartisPhase 2
52

Other Products from Gesynta Pharma

GS-248 + PlaceboPhase 2
44
Formulation A GS-248 + Formulation B GS-248Phase 1
25
GS-248 + PlaceboPhase 1
25